

Triterpenoids from the Leaves of *Ilex hainanensis*

by Si-Xiang Zhou^{a)}), Jun-Shan Yang^{*a)}, Fu-Cheng Liu^{a)}, and Peng-Fei Tu^{*b)}


^{a)} Institute of Medicinal Plant Development, Peking Union Medical College & Chinese Academy of Medical Sciences, 151 Malianwa North Road, Haidian District, Beijing 100094, P. R. China (phone: +86-10-62899707; fax: +86-10-62898425; e-mail: junshanyang@hotmail.com)

^{b)} School of Pharmaceutical Sciences, Peking University Health Science Center, 38 Xueyuan Road, Beijing 100083, P. R. China (phone/fax: +86-10-82802750; e-mail: pengfeitu@bjmu.edu.cn)

Phytochemical investigation on the leaves of *Ilex hainanensis* MERR. led to the isolation of four new ursane- and oleanane-based triterpenoids, ilexhainanins A–D (**1–4**), as well as two known compounds, $2\alpha,3\beta,19\alpha$ -trihydroxyurs-12-ene-23,28-dioic acid and $2\alpha,3\beta,19\alpha$ -trihydroxyolean-12-ene-23,28-dioic acid. Their structures were elucidated on the basis of chemical and spectroscopic evidence, and by comparison with literature data.

Introduction. – *Ilex hainanensis* MERR. (Aquifoliaceae) is distributed mainly in the southern region of the People's Republic of China. The leaves of this plant is a traditional tea product, known as 'shan-lv-cha'. It is also used in traditional Chinese medicine (TCM) as a diuretic, antihypertensive, antilipemic, and anti-inflammatory agent. There are numerous clinical research reports on the use of 'shan-lv-cha' for treatment of hypertension [1]. However, only a few phytochemical investigations have been performed, and as few as five compounds have been isolated from *I. hainanensis* [2][3]. Therefore, a more systematic chemical investigation was carried out.

Herein, we report four new triterpenoids, ilexhainanins A–D (**1–4**), from the leaves of *I. hainanensis*. They were isolated together with the two known constituents $2\alpha,3\beta,19\alpha$ -trihydroxyurs-12-ene-23,28-dioic acid [4] and $2\alpha,3\beta,19\alpha$ -trihydroxyolean-12-ene-23,28-dioic acid [5].



Results and Discussion. – Compound **1** was obtained as an optically active powder ($[\alpha]_D^{26} = +42.3$ ($c = 1.3$, MeOH)). It gave rise to a positive *Liebermann–Burchard* coloration test, indicating a triterpenoid structure. The molecular formula $C_{30}H_{46}O_6$ was deduced by negative-ion HR-ESI-MS (m/z 501.3217 ($[M-H]^-$)), in accord with eight degrees of unsaturation. The IR spectrum of **1** showed characteristic bands for OH (3401) and C=O (1692 cm^{-1}) groups. The 1H - and ^{13}C -NMR data of **1** (Table 1) indicated a pentacyclic triterpenoid, assignments being confirmed with the help of 2D-NMR (HMBC, HSQC, NOESY) experiments.

The 1H -NMR spectrum of **1** (Table 1) revealed the presence of four Me groups at $\delta(H)$ 1.08 (2s), 1.25 (s), and 1.70 (s), a Me doublet at $\delta(H)$ 1.15 ($J = 6.5$ Hz), one olefinic signal at $\delta(H)$ 5.52 (br. s, H–C(12)), and a characteristic signal for H–C(18) at $\delta(H)$ 2.73 (d, $J = 12$ Hz). The ^{13}C -NMR spectrum indicated a C=C bond ($\delta(C)$ 125.8, 139.1), two COOH groups ($\delta(C)$ 180.9, 179.9), and two oxygenated C-atoms ($\delta(C)$ 78.2 (OCH), 65.1 (OCH₂)). The above data pointed to a triterpenoid with an urs-12-ene skeleton.

A typical signal of an axial H–C(3) atom at $\delta(H)$ 3.34 (dd, $J = 12.0, 4.0$ Hz) was observed, indicating a β -equatorial orientation of the 3-OH group in **1** [6]. In the HMBC spectrum (Fig. 1, a), correlation peaks were observed from $\delta(H)$ 3.34 (H–C(3)) to $\delta(C)$ 180.9 (COOH) and 24.7 (Me), and from $\delta(H)$ 1.70 (Me) to $\delta(C)$ 180.9, 78.2 (C(3)), and 49.2 (C(4)), which indicated that a COOH and a Me group were both attached to C(4), the Me(23) group being in α -equatorial position, on the basis of its ^{13}C -NMR chemical shift (Table 1) [7]. The HMBC correlation between $\delta(H)$ 2.73 (H–C(18)) and $\delta(C)$ 179.9 indicated that the second COOH group (C(28)) was linked at C(17). The second OH group was placed at C(30), on the basis of NMR resonances at $\delta(H)$ 3.91, 3.97 (2dd, $J = 5.5, 2.5$ Hz each) in combination with HMBC analysis (Fig. 1, a).




Fig. 1. Key HMBC correlations of a) **1** and b) **2**

The relative configuration of **1** was confirmed by a NOESY experiment. The 3β -OH, 4α -Me, and 4β -COOH groups were in accord with the following NOESY correlations: H–C(3)/H–C(5) [$\delta(H)$ 1.03–1.07 (*m*)], H–C(3)/Me(23) ($\delta(H)$ 1.70 (s, 3 H)), and Me(23)/H–C(5). The correlations between H–C(18) and Me(29) ($\delta(H)$ 1.15 (d, $J = 6.5$ Hz)), and between H–C(18) and H–C(20) ($\delta(H)$ 1.26–1.30 (*m*)) indicated an α -configured CH₂OH group at C(20). From the above evidence, the structure of com-

Table 1. ^1H - and ^{13}C -NMR Data of **1** and **2**. At 500 (^1H) and 125 MHz (^{13}C), in $\text{C}_5\text{D}_5\text{N}$; δ in ppm, J in Hz.

Position	1		2	
	$\delta(\text{C})$	$\delta(\text{H})$	$\delta(\text{C})$	$\delta(\text{H})$
1	39.7	1.02–1.06 (<i>m</i>) 1.64–1.70 (<i>m</i>)	39.6	1.04–1.10 (<i>m</i>) 1.58–1.62 (<i>m</i>)
2	29.5	1.24–1.26 (<i>m</i>) 1.30–1.32 (<i>m</i>)	29.5	1.26–1.30 (<i>m</i>)
3	78.2	3.34 (<i>dd</i> , $J=14.0, 4.0$)	78.2	3.34 (<i>dd</i> , $J=14.0, 4.0$)
4	49.2		49.2	
5	56.8	1.03–1.07 (<i>m</i>)	56.8	1.06–1.10 (<i>m</i>)
6	20.7	2.02–2.08 (<i>m</i>) 2.10–2.16 (<i>m</i>)	20.8	2.02–2.08 (<i>m</i>) 2.10–2.16 (<i>m</i>)
7	33.9	1.40–1.46 (<i>m</i>) 1.48–1.56 (<i>m</i>)	33.5	1.46–1.56 (<i>m</i>)
8	39.8		39.5	
9	47.3	1.60–1.64 (<i>m</i>)	47.4	1.60–1.64 (<i>m</i>)
10	37.8		37.8	
11	23.8	1.92–2.00 (<i>m</i>)	24.0	1.94–2.02 (<i>m</i>)
12	125.8	5.52 (<i>br. s</i>)	122.6	5.59 (<i>br. s</i>)
13	139.1		144.8	
14	42.6		42.2	
15	29.0	1.88–1.96 (<i>m</i>) 2.38–2.44 (<i>m</i>)	28.3	1.08–1.12 (<i>m</i>) 2.10–2.16 (<i>m</i>)
16	25.0	1.98–2.04 (<i>m</i>) 2.20–2.26 (<i>m</i>)	23.8	1.90–1.94 (<i>m</i>) 2.12–2.16 (<i>m</i>)
17	48.3		47.2	
18	53.6	2.73 (<i>d</i> , $J=12.0$)	41.5	3.41 (<i>dd</i> , $J=14.0, 4.0$)
19	33.9	1.98–2.06 (<i>m</i>)	41.2	1.46–1.50 (<i>m</i>) 2.06–2.10 (<i>m</i>)
20	47.4	1.26–1.30 (<i>m</i>)	36.6	
21	25.7	1.56–1.62 (<i>m</i>) 1.94–1.98 (<i>m</i>)	29.0	1.35–1.39 (<i>m</i>) 1.76–1.80 (<i>m</i>)
22	37.4	1.98–2.04 (<i>m</i>) 2.08–2.10 (<i>m</i>)	32.6	1.86–1.90 (<i>m</i>) 2.10–2.14 (<i>m</i>)
23	24.7	1.70 (<i>s</i>)	24.7	1.69 (<i>s</i>)
24	180.9		180.9	
25	14.0	1.08 (<i>s</i>)	13.8	1.06 (<i>s</i>)
26	17.4	1.08 (<i>s</i>)	17.3	1.08 (<i>s</i>)
27	23.8	1.25 (<i>s</i>)	26.0	1.29 (<i>s</i>)
28	179.9		180.2	
29	17.2	1.15 (<i>d</i> , $J=6.5$)	73.8	3.60 (<i>s</i>)
30	65.1	3.91 (<i>dd</i> , $J=5.5, 2.5$) 3.97 (<i>dd</i> , $J=5.5, 2.5$)	19.8	1.20 (<i>s</i>)

pound **1** was unequivocally established as (3 β)-3,30-dihydroxyurs-12-ene-24,28-dioic acid, and named *ilexhainanin A*.

Compound **2**, isolated as a colorless, amorphous powder, gave a positive *Liebermann–Burchard* coloration test. Its molecular formula was $\text{C}_{30}\text{H}_{46}\text{O}_6$ according to HR-ESI-MS (m/z 501.3218 ($[\text{M} - \text{H}]^-$)), corresponding to eight degrees of unsatura-

tion. The compound was optically active, with $[\alpha]_{\text{D}}^{26} = +53.5$ ($c = 2.3$, MeOH). The IR spectrum revealed the presence of OH (3430) and C=O (1692 cm^{-1}) groups. The ^1H -NMR spectrum of **2** showed signals of five Me *singlets* at $\delta(\text{H})$ 1.06, 1.08, 1.20, 1.29, 1.69, one olefinic H-atom at $\delta(\text{H})$ 5.59 (br. *s*), and a characteristic signal for H–C(18) at $\delta(\text{H})$ 3.41 (*dd*, $J = 14.0, 4.0$ Hz). The ^{13}C -NMR spectrum indicated one C=C bond ($\delta(\text{C})$ 122.6, 144.8), two COOH functions ($\delta(\text{C})$ 180.2, 180.9), and two oxygenated C-atoms ($\delta(\text{C})$ 73.8 (HOCH₂), 78.2 (OCH)). The above evidence suggested that compound **2** was a triterpenoid with an olean-12-ene C skeleton, and an isomer of compound **1**.

Careful comparison of the ^{13}C -NMR spectroscopic data of **2** with those of **1** showed that the signals for C(1) to C(11) and C(23) to C(26) were basically identical in both compounds, which indicated identical rings *A*, *B*, and *C*. To confirm the substitution pattern of **2** in ring *E*, the known triterpenoid (3 β)-3,29-dihydroxyolean-12-ene-23,28-dioic acid [8] was used as a reference compound. The signals of C(12) to C(22) and of C(27) to C(30) of **2** matched well with those of the known triterpenoid, which suggested that their *C*-, *D*-, and *E*-rings were similar. The NMR data assignments were further corroborated by HSQC and HMBC correlations (Fig. 1, *b*). Thus, based on the above evidence, the structure of compound **2** was elucidated as (3 β)-3,29-dihydroxyolean-12-ene-24,28-dioic acid, and named *ilexhainanin B*.

Compound **3**, isolated as an amorphous powder and showing a positive *Liebermann–Burchard* test, was found to have the molecular formula C₃₀H₄₆O₇ by HR-ESI-MS (m/z 517.3168 ($[M - \text{H}]^-$), indicating eight degrees of unsaturation. It was optically active, with $[\alpha]_{\text{D}}^{26} = +28.8$ ($c = 0.9$, MeOH). The IR spectrum indicated the presence of OH (3427) and C=O (1690 cm^{-1}) groups. These data, together with a comparison of the ^1H - and ^{13}C -NMR data of **3** (Table 2) with those of **1**, indicated that **3** was a triterpenoid with an urs-12-ene C skeleton.

The ^{13}C -NMR spectrum of **3** indicated two COOH groups ($\delta(\text{C})$ 179.2, 180.6), three oxygenated C-atoms ($\delta(\text{C})$ 64.4 (HOCH₂), 73.2 (OCH), and 72.6 (C_q)). Oxygenation at C(19) was inferred from the low-field-shifted signal at $\delta(\text{C})$ 72.6 (C(19)) showing long-range HMBC correlations with H–C(18) ($\delta(\text{H})$ 3.03 (br. *s*)), Me(29) ($\delta(\text{H})$ 1.43 (*s*)), and Me(30) ($\delta(\text{H})$ 1.10 (*d*, $J = 6.5$ Hz)). The second OH group was considered to be at C(3). Its β -configuration was derived from the coupling pattern of axial H–C(3) ($\delta(\text{H})$ 4.21 (*dd*, $J = 13.0, 4.0$ Hz)). Careful comparison of the ^1H - and ^{13}C -NMR data of **3** with those of *ilexagenin A* (=3 β ,19 α -dihydroxyurs-12-ene-24,28-dioic-acid) [9] exhibited differences only in ring *A*. Thus, the signal for Me(23), which was observed at $\delta(\text{H})$ 1.70 and $\delta(\text{C})$ 24.7 in *ilexagenin A*, was not present in **3**; instead, the signals of a CH₂OH group were detected in **3** ($\delta(\text{H})$ 4.39, 4.73 (*AB*-type *q*, $J = 10.5$ Hz); $\delta(\text{C})$ 64.4). Both a COOH and a CH₂OH group were attached to C(4), as confirmed by the key HMBC correlations (Fig. 2, *a*) from $\delta(\text{H})$ 4.21 (H–C(3)) to $\delta(\text{C})$ 179.2 (COOH) and $\delta(\text{C})$ 64.4 (CH₂OH), and from $\delta(\text{H})$ 4.39, 4.73 (CH₂(23)) to $\delta(\text{C})$ 179.2 (C(24)), $\delta(\text{C})$ 55.1 (C(4)), and $\delta(\text{C})$ 73.2 (C(3)). The HMBC correlations between $\delta(\text{H})$ 3.03 (H–C(18)) and $\delta(\text{C})$ 180.6 confirmed that the second COOH group was linked at C(17).

The relative configuration of **3** was deduced by a NOESY experiment. The 3 β -OH, 4 β -COOH, and 4 α -CH₂OH groups were in accord with the following NOESY correlations: H–C(3)/H–C(5) and H–C(3)/CH₂(23). Further, H–C(18) correlated with

Table 2. ^1H - and ^{13}C -NMR Data of **3** and **4**. At 500 (^1H) and 125 MHz (^{13}C) in $\text{C}_5\text{D}_5\text{N}$; δ in ppm, J in Hz.

Position	3		4	
	$\delta(\text{C})$	$\delta(\text{H})$	$\delta(\text{C})$	$\delta(\text{H})$
1	39.6	1.08–1.16 (<i>m</i>) 1.68–1.72 (<i>m</i>)	39.3	1.08–1.16 (<i>m</i>) 1.68–1.72 (<i>m</i>)
2	29.3	1.20–1.30 (<i>m</i>)	29.2	1.10–1.20 (<i>m</i>)
3	73.2	4.21 (<i>dd</i> , $J=13.0, 4.0$)	73.0	4.21 (<i>dd</i> , $J=13.0, 4.0$)
4	55.1		55.1	
5	49.3	1.82–1.86 (<i>m</i>)	49.3	1.82–1.86 (<i>m</i>)
6	20.7	2.20–2.28 (<i>m</i>)	20.7	2.16–2.24 (<i>m</i>)
7	33.6	1.44–1.48 (<i>m</i>) 1.98–2.02 (<i>m</i>)	33.6	1.70–1.76 (<i>m</i>) 2.12–2.16 (<i>m</i>)
8	40.2		39.8	
9	47.3	1.90–1.94 (<i>m</i>)	47.9	1.86–1.90 (<i>m</i>)
10	37.6		37.8	
11	24.3	2.00–2.10 (<i>m</i>)	24.3	2.00–2.10 (<i>m</i>)
12	128.0	5.95 (<i>br. s</i>)	123.0	5.56 (<i>br. s</i>)
13	139.9		144.8	
14	42.3		42.2	
15	29.3	2.06–2.14 (<i>m</i>) 2.26–2.32 (<i>m</i>)	29.1	2.06–2.14 (<i>m</i>) 2.26–2.32 (<i>m</i>)
16	26.4	1.98–2.06 (<i>m</i>)	27.0	2.00–2.10 (<i>m</i>)
17	48.2		46.0	
18	54.6	3.03 (<i>br. s</i>)	44.8	3.60 (<i>br. s</i>)
19	72.6		81.0	3.60 (<i>br. s</i>)
20	42.3	1.46–1.50 (<i>m</i>)	35.5	
21	27.0	1.30–1.34 (<i>m</i>) 1.40–1.44 (<i>m</i>)	28.4	2.06–2.12 (<i>m</i>) 2.76–2.80 (<i>m</i>)
22	38.4	1.98–2.06 (<i>m</i>) 2.08–2.16 (<i>m</i>)	33.3	1.38–1.42 (<i>m</i>) 1.60–1.66 (<i>m</i>)
23	64.4	4.39, 4.73 (<i>AB q</i> , $J=10.5$)	64.3	4.40, 4.74 (<i>AB q</i> , $J=10.5$)
24	179.2		179.2	
25	14.3	1.20 (<i>s</i>)	14.1	1.20 (<i>s</i>)
26	17.1	1.16 (<i>s</i>)	17.3	1.16 (<i>s</i>)
27	24.5	1.68 (<i>s</i>)	24.6	1.60 (<i>s</i>)
28	180.6		180.8	
29	26.9	1.43 (<i>s</i>)	28.8	1.18 (<i>s</i>)
30	16.7	1.10 (<i>d</i> , $J=6.5$)	24.8	1.09 (<i>s</i>)

Me(29) ($\delta(\text{H})$ 1.43 (*s*)), which indicated an α -OH group at C(19). On the basis of the above evidence, the structure of compound **3** was, thus, determined as (3 β ,19*R*)-3,19,23-trihydroxyurs-12-ene-24,28-dioic acid, and named *ilexhainanin C*.

Compound **4**, obtained as an amorphous powder, also gave a positive *Liebermann–Burchard* test. The molecular formula of **4** was determined as $\text{C}_{30}\text{H}_{46}\text{O}_7$ by HR-ESI-MS (m/z 517.3169 ($[M-\text{H}]^-$)), suggesting eight degrees of unsaturation. The compound was optically active, with $[\alpha]_{\text{D}}^{26} = +36.6$ ($c=1.0$, MeOH). The IR spectrum showed signals for OH (3428) and C=O (1690 cm^{-1}) groups. The above data, together with a detailed comparison of its ^1H - and ^{13}C -NMR data (*Table 2*) with those of **2**, manifested




Fig. 2. Key HMBC correlations of a) **3** and b) **4**

that **4** was an isomer of **3**. By comparing their ^{13}C -NMR spectroscopic data, in combination with those of the known triterpenoid ilexolic acid B (= $3\beta,19\alpha$ -dihydroxyolean-12-ene-23,28-dioic acid) [10], rings A–C of **4** were similar to those of **3**, and rings C–E of **4** were similar to those of ilexolic acid B, respectively. NMR Assignments were confirmed with the help of HSQC and HMBC experiments (Fig. 2, b). Accordingly, the structure of **4** was unambiguously established as ($3\beta,19\alpha$)-3,19,23-trihydroxyolean-12-ene-24,28-dioic acid, and named *ilexhainanin D*.

The two known compounds, $2\alpha,3\beta,19\alpha$ -trihydroxyurs-12-ene-23,28-dioic acid [4] and $2\alpha,3\beta,19\alpha$ -trihydroxyolean-12-ene-23,28-dioic acid [5], were identified by comparison of their spectroscopic data with those reported in the literature.

The authors thank the *National Science Foundation of China* for financial support (No. 30672608). This work was also supported by the program for Changjiang Scholar and Innovative Team in University (No. 985-2-063-112).

Experimental Part

General. Column chromatography (CC): silica gel *H* (200–300 mesh; *Qingdao Marine Chemical Industry*), *Sephadex LH-20* gel (*Pharmacia*), *ODS* gel (25–40 μm ; *Merck*), and *D101* porous polymer resin (*Tianjin Chemical Industry*). Semi-prep. HPLC: *ODS* column (250 \times 10 mm, 5 μm ; *Alltech*), with *ELSD* detector (*Alltech*); flow rate, 2.5 ml/min. Optical rotations: *Perkin-Elmer-243B* digital polarimeter. NMR Spectra: *Varian Inova-500* apparatus; at 500 (^1H) or 125 MHz (^{13}C) in $\text{C}_5\text{D}_5\text{N}$ at r.t.; δ in ppm rel. to Me_4Si , *J* in Hz. HR-ESI-MS (neg.): *Bruker APEX-II FT-ICR-MS* mass spectrometer; in *m/z*.

Plant Material. The leaves of *Ilex hainanensis* were purchased in Guangxi Province, South China, in March 2005, and identified by Prof. P.-F. Tu. A voucher specimen (SLC 200503) was deposited at the Herbarium of Peking University, Modern Research Center for Traditional Chinese Medicine.

Extraction and Isolation. The air-dried leaves (20 kg) of *I. hainanensis* were extracted with 70% aq. EtOH at 60° (3 \times). The combined extract was concentrated under vacuum, and the residue (1.7 kg) was suspended in H_2O , and extracted first with CHCl_3 and then with BuOH. The BuOH-soluble extract (300 g) was dissolved in H_2O , and the water-dissolved fraction (190 g) was subjected to CC (*D101* porous polymer resin; 1. H_2O , 2. 10, 30, 50, 70, and 95% aq. EtOH). The fraction eluted with 70% aq. EtOH (20 g) was subjected to CC (SiO_2 ; $\text{CHCl}_3/\text{MeOH}/\text{H}_2\text{O}$ 20:1:0 \rightarrow 7:3:0.5) to afford 10 subfractions (*Fr. 1–10*). *Fr. 2* was purified by CC (1. *Sephadex LH-20*, MeOH; 2. *ODS*, 70% aq. MeOH) followed by semi-prep. HPLC (MeOH/ H_2O 2:1) to furnish **1** (13 mg) and **2** (23 mg). *Fr. 5* was subjected to CC (1. *Sephadex LH-20*, MeOH; 2. *ODS*, 65% aq. MeOH) followed by semi-prep. HPLC (MeOH/ H_2O 2:1)

to afford **3** (9 mg) and **4** (10 mg). Purification of *Fr. 8* by CC (ODS; 60% aq. MeOH) and then by semi-prep. HPLC (MeCN/H₂O 35:65) afforded the two known compounds 2 α ,3 β ,19 α -trihydroxyurs-12-ene-23,28-dioic acid (12 mg) [4] and 2 α ,3 β ,19 α -trihydroxyolean-12-ene-23,28-dioic acid (13 mg) [5].

Ilexhainanin A (= (3 β)-3,30-Dihydroxyurs-12-ene-24,28-dioic Acid; **1**). Colorless, amorphous powder. $[\alpha]_D^{26} = +42.3$ ($c = 1.3$, MeOH). IR (KBr): 3401, 1692. ¹H- and ¹³C-NMR: see *Table 1*. HR-ESI-MS: 501.3217 ($[M - H]^-$), C₃₀H₄₅O₆⁻; calc. 501.3216).

Ilexhainanin B (= (3 β)-3,29-Dihydroxyolean-12-ene-24,28-dioic Acid; **2**). Colorless, amorphous powder. $[\alpha]_D^{26} = +53.5$ ($c = 2.3$, MeOH). IR (KBr): 3430, 1692. ¹H- and ¹³C-NMR: see *Table 1*. HR-ESI-MS: 501.3218 ($[M - H]^-$), C₃₀H₄₅O₆⁻; calc. 501.3216).

Ilexhainanin C (= (3 β ,19R)-3,19,23-Trihydroxyurs-12-ene-24,28-dioic Acid; **3**). Colorless, amorphous powder. $[\alpha]_D^{26} = +28.8$ ($c = 0.9$, MeOH). IR (KBr): 3427, 1690. ¹H- and ¹³C-NMR: see *Table 2*. HR-ESI-MS: 517.3168 ($[M - H]^-$), C₃₀H₄₅O₇⁻; calc. 517.3165).

Ilexhainanin D (= (3 β ,19 α)-3,19,23-Trihydroxyolean-12-ene-24,28-dioic Acid; **4**). Colorless, amorphous powder. $[\alpha]_D^{26} = +36.6$ ($c = 1.0$, MeOH). IR (KBr): 3428, 1690. ¹H- and ¹³C-NMR: see *Table 2*. HR-ESI-MS: 517.3169 ($[M - H]^-$), C₃₀H₄₅O₇⁻; calc. 517.3165).

REFERENCES

- [1] Y. Chen, Z. Xie, J. Liu, H. Xin, *J. Gungxi Tradit. Chin. Med. Univ.* **2004**, 7, 4.
- [2] Z.-D. Ming, K.-H. Qin, *Acta Pharm. Sin.* **1984**, 28, 2827.
- [3] D.-X. Wen, X.-Z. Zheng, *China J. Chin. Materia Med.* **1999**, 24, 223.
- [4] F. Gao, F.-H. Chen, T. Tanaka, R. Kasai, T. Seto, O. Tanaka, *Chem. Pharm. Bull.* **1985**, 33, 37.
- [5] B.-G. Wang, Z.-J. Jia, *Phytochemistry* **1998**, 49, 185.
- [6] M.-A. Ouyang, C.-R. Yang, Z.-L. Chen, H.-Q. Wang, *Phytochemistry* **1996**, 41, 871.
- [7] S. B. Mahato, A. P. Kundu, *Phytochemistry* **1994**, 37, 1517.
- [8] M. Hani, A. Elgamal, H. S. M. Soliman, *Magn. Reson. Chem.* **1996**, 34, 697.
- [9] M. Nakatani, Y. Miyazaki, T. Iwashita, H. Naoki, T. Hase, *Phytochemistry* **1989**, 28, 1479.
- [10] K. Amimoto, K. Yoshikawa, S. Arihara, *Phytochemistry* **1993**, 33, 1475.

Received September 27, 2006